Last reviewed · How we verify
NCT05124106
In Vivo Proof-of-principle Study of Raman Spectroscopy in Trial Participants With Bladder Tumours
Phase 1 trial testing Raman Spectrometry in Endoscopic Bladder Cancer Diagnosis With Raman in 30 participants. Status unknown.
1 February 2022
Quick facts
| Lead sponsor | University Hospital Bispebjerg and Frederiksberg |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 22 November 2021 |
| Primary completion | 1 February 2022 |
| Estimated completion | 1 April 2022 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Raman Spectrometry
Conditions studied
- Endoscopic Bladder Cancer Diagnosis With Raman — all drugs for Endoscopic Bladder Cancer Diagnosis With Raman →
Sponsor
University Hospital Bispebjerg and Frederiksberg
Who can join
18 and older, any sex, with Endoscopic Bladder Cancer Diagnosis With Raman. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose with this clinical investigation is to perform Raman spectroscopy inside the vivid bladder and to acquire Raman spectra of normal and tumour bladder tissue, and in a post-processing step to determine the grade of the tumor.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Raman Spectroscopy for Instant Bladder Tumor Diagnosis: System Development and In Vivo Proof-Of-Principle Study in Accordance with the European Medical Device Regulation (MDR2017/745).
Latka I, Mogensen K, Knorr F, Kuzucu C, et al · · 2024 · cited 3× · PMID 39335209 · DOI 10.3390/cancers16183238
Verify or expand the search:
- PubMed search for NCT05124106
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Raman Spectrometry
Trials testing the same drug.
- NCT05995990 — Raman Spectroscopy for Liver Tumours Following Liver Surgery · NA · completed
Other University Hospital Bispebjerg and Frederiksberg trials
Trials by the same sponsor.
- NCT07060586 — The Effect of Sphenopalatine Ganglion Block on Headache and Vasalgia · NA · completed
- NCT06911411 — PALLIATIVE ASSESSMENT COHORT IN THE GERIATRIC EMERGENCY SETTING · not yet recruiting
- NCT06405750 — Left Atrial Appendage Arrhythmogenic and Thrombogenic Substrate · NA · recruiting
- NCT06532825 — Cardiac Autonomic Dysfunction As a Sign of Irreversible Advanced Heart Failure · recruiting
- NCT06184581 — Lithium Versus Lamotrigine in Bipolar Disorder, Type II · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05124106 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Bispebjerg and Frederiksberg
- Last refreshed: 13 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05124106.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing